THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Joan Merrill to Adult

This is a "connection" page, showing publications Joan Merrill has written about Adult.
Connection Strength

2.597
  1. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
    View in: PubMed
    Score: 0.086
  2. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
    View in: PubMed
    Score: 0.084
  3. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 10 01; 59(10):2930-2938.
    View in: PubMed
    Score: 0.078
  4. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes. 2019 Jun 07; 17(1):99.
    View in: PubMed
    Score: 0.071
  5. The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome. Bull Hosp Jt Dis (2013). 2019 Mar; 77(2):92-98.
    View in: PubMed
    Score: 0.070
  6. Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. Arthritis Care Res (Hoboken). 2018 07; 70(7):1058-1063.
    View in: PubMed
    Score: 0.066
  7. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
    View in: PubMed
    Score: 0.065
  8. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
    View in: PubMed
    Score: 0.065
  9. The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
    View in: PubMed
    Score: 0.062
  10. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
    View in: PubMed
    Score: 0.060
  11. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. Arthritis Res Ther. 2016 09 02; 18:197.
    View in: PubMed
    Score: 0.059
  12. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
    View in: PubMed
    Score: 0.054
  13. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014 Feb; 66(2):379-89.
    View in: PubMed
    Score: 0.049
  14. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
    View in: PubMed
    Score: 0.045
  15. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1726-32.
    View in: PubMed
    Score: 0.042
  16. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
    View in: PubMed
    Score: 0.041
  17. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct; 62(10):3077-87.
    View in: PubMed
    Score: 0.039
  18. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
    View in: PubMed
    Score: 0.037
  19. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
    View in: PubMed
    Score: 0.022
  20. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
    View in: PubMed
    Score: 0.021
  21. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
    View in: PubMed
    Score: 0.021
  22. Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis Rheumatol. 2021 12; 73(12):2293-2302.
    View in: PubMed
    Score: 0.021
  23. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
    View in: PubMed
    Score: 0.021
  24. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford). 2021 10 02; 60(10):4737-4747.
    View in: PubMed
    Score: 0.021
  25. Appropriate management of antiphospholipid-related pregnancy in women without lupus who have low titer autoantibodies. Curr Rheumatol Rep. 2001 Aug; 3(4):269-70.
    View in: PubMed
    Score: 0.021
  26. Which antiphospholipid antibody tests are most useful? Rheum Dis Clin North Am. 2001 Aug; 27(3):525-49.
    View in: PubMed
    Score: 0.021
  27. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
    View in: PubMed
    Score: 0.020
  28. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2020 10; 72(10):1734-1740.
    View in: PubMed
    Score: 0.019
  29. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
    View in: PubMed
    Score: 0.019
  30. Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Res Ther. 2020 03 19; 22(1):52.
    View in: PubMed
    Score: 0.019
  31. Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
    View in: PubMed
    Score: 0.019
  32. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Rheumatol. 2020 04; 72(4):658-666.
    View in: PubMed
    Score: 0.019
  33. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020 03; 79(3):356-362.
    View in: PubMed
    Score: 0.018
  34. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020 01; 72(1):67-77.
    View in: PubMed
    Score: 0.018
  35. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020 01; 106:102340.
    View in: PubMed
    Score: 0.018
  36. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019 07 01; 58(7):1259-1267.
    View in: PubMed
    Score: 0.018
  37. Immunologic findings precede rapid lupus flare after transient steroid therapy. Sci Rep. 2019 06 13; 9(1):8590.
    View in: PubMed
    Score: 0.018
  38. Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res (Hoboken). 2019 07; 71(7):893-902.
    View in: PubMed
    Score: 0.018
  39. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.
    View in: PubMed
    Score: 0.018
  40. Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 08; 71(8):1297-1307.
    View in: PubMed
    Score: 0.018
  41. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. J Rheumatol. 2020 01; 47(1):72-81.
    View in: PubMed
    Score: 0.018
  42. Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. J Exp Med. 2019 05 06; 216(5):1154-1169.
    View in: PubMed
    Score: 0.018
  43. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019 02; 71(2):281-289.
    View in: PubMed
    Score: 0.017
  44. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. J Rheumatol. 2019 05; 46(5):492-500.
    View in: PubMed
    Score: 0.017
  45. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Ann Rheum Dis. 2019 07; 78(7):1010-1012.
    View in: PubMed
    Score: 0.017
  46. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken). 2018 10; 70(10):1478-1487.
    View in: PubMed
    Score: 0.017
  47. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 07; 70(7):1071-1076.
    View in: PubMed
    Score: 0.016
  48. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford). 2018 04 01; 57(4):677-687.
    View in: PubMed
    Score: 0.016
  49. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018 04; 77(4):549-555.
    View in: PubMed
    Score: 0.016
  50. Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2018 02; 70(2):230-235.
    View in: PubMed
    Score: 0.016
  51. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Res Ther. 2017 12 22; 19(1):287.
    View in: PubMed
    Score: 0.016
  52. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. J Rheumatol. 2018 04; 45(4):456-464.
    View in: PubMed
    Score: 0.016
  53. Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken). 2017 12; 69(12):1780-1788.
    View in: PubMed
    Score: 0.016
  54. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997 Jun; 24(6):1083-8.
    View in: PubMed
    Score: 0.015
  55. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017 Jun 07; 12(6):940-946.
    View in: PubMed
    Score: 0.015
  56. Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis Rheumatol. 2017 04; 69(4):785-790.
    View in: PubMed
    Score: 0.015
  57. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol. 2017 03; 69(3):643-654.
    View in: PubMed
    Score: 0.015
  58. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017 Sep; 26(10):1051-1059.
    View in: PubMed
    Score: 0.015
  59. Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun. 2017 03; 78:70-78.
    View in: PubMed
    Score: 0.015
  60. Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 02; 69(2):376-386.
    View in: PubMed
    Score: 0.015
  61. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. 2016 10; 68(10):2492-502.
    View in: PubMed
    Score: 0.015
  62. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.
    View in: PubMed
    Score: 0.015
  63. Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares. Arthritis Rheumatol. 2016 09; 68(9):2200-9.
    View in: PubMed
    Score: 0.015
  64. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis Rheumatol. 2016 08; 68(8):1964-9.
    View in: PubMed
    Score: 0.015
  65. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis Rheumatol. 2016 08; 68(8):1932-44.
    View in: PubMed
    Score: 0.015
  66. Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr; 68(4):534-43.
    View in: PubMed
    Score: 0.014
  67. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
    View in: PubMed
    Score: 0.014
  68. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.014
  69. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb; 55(2):252-62.
    View in: PubMed
    Score: 0.014
  70. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
    View in: PubMed
    Score: 0.014
  71. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015 Aug 04; 163(3):153-63.
    View in: PubMed
    Score: 0.014
  72. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2015 Jul; 67(7):1837-47.
    View in: PubMed
    Score: 0.013
  73. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan; 75(1):196-202.
    View in: PubMed
    Score: 0.013
  74. Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J Autoimmun. 2015 Jul; 61:29-35.
    View in: PubMed
    Score: 0.013
  75. Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
    View in: PubMed
    Score: 0.013
  76. Genetic association of CD247 (CD3?) with SLE in a large-scale multiethnic study. Genes Immun. 2015 Mar; 16(2):142-50.
    View in: PubMed
    Score: 0.013
  77. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). 2015 Jan; 67(1):128-35.
    View in: PubMed
    Score: 0.013
  78. Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol. 2015 Feb 01; 194(3):940-9.
    View in: PubMed
    Score: 0.013
  79. Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol. 2014 Dec; 66(12):3404-12.
    View in: PubMed
    Score: 0.013
  80. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
    View in: PubMed
    Score: 0.013
  81. Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis. 2016 Jan; 75(1):242-52.
    View in: PubMed
    Score: 0.013
  82. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1167-76.
    View in: PubMed
    Score: 0.013
  83. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol. 2014 Jul; 66(7):1888-99.
    View in: PubMed
    Score: 0.013
  84. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep; 74(9):1706-13.
    View in: PubMed
    Score: 0.012
  85. Dynamic state of beta 2 integrin phosphorylation: regulation of neutrophil aggregation involves a phosphatase-dependent pathway. Clin Immunol Immunopathol. 1994 May; 71(2):216-22.
    View in: PubMed
    Score: 0.012
  86. American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol. 2014 May; 41(5):875-80.
    View in: PubMed
    Score: 0.012
  87. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015 Aug; 74(8):1530-6.
    View in: PubMed
    Score: 0.012
  88. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014 Feb; 66(2):390-6.
    View in: PubMed
    Score: 0.012
  89. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov; 65(11):2887-97.
    View in: PubMed
    Score: 0.012
  90. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
    View in: PubMed
    Score: 0.012
  91. Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. J Rheumatol. 2013 Jun; 40(6):842-9.
    View in: PubMed
    Score: 0.012
  92. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmun. 2013 Jun; 43:78-84.
    View in: PubMed
    Score: 0.012
  93. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther. 2013 Mar 20; 15(2):R44.
    View in: PubMed
    Score: 0.012
  94. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther. 2013; 15(6):R212.
    View in: PubMed
    Score: 0.011
  95. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum. 2012 Nov; 64(11):3687-94.
    View in: PubMed
    Score: 0.011
  96. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013 Aug; 72(8):1308-14.
    View in: PubMed
    Score: 0.011
  97. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012 Jul; 64(7):2311-8.
    View in: PubMed
    Score: 0.011
  98. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov; 71(11):1833-8.
    View in: PubMed
    Score: 0.011
  99. Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. J Autoimmun. 2012 May; 38(2-3):J216-22.
    View in: PubMed
    Score: 0.011
  100. Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum. 2012 Feb; 64(2):485-92.
    View in: PubMed
    Score: 0.011
  101. Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis. J Rheumatol. 2012 Mar; 39(3):510-5.
    View in: PubMed
    Score: 0.011
  102. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan; 64(1):132-7.
    View in: PubMed
    Score: 0.011
  103. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
    View in: PubMed
    Score: 0.011
  104. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum. 2011 Dec; 63(12):3931-41.
    View in: PubMed
    Score: 0.011
  105. Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum. 2011 Sep; 63(9):2755-63.
    View in: PubMed
    Score: 0.010
  106. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 2011 Aug; 63(8):2396-406.
    View in: PubMed
    Score: 0.010
  107. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1752-7.
    View in: PubMed
    Score: 0.010
  108. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011 May; 6(5):593-601.
    View in: PubMed
    Score: 0.010
  109. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Jun; 70(6):961-7.
    View in: PubMed
    Score: 0.010
  110. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(4):R146.
    View in: PubMed
    Score: 0.010
  111. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun; 62(6):881-7.
    View in: PubMed
    Score: 0.009
  112. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
    View in: PubMed
    Score: 0.009
  113. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
    View in: PubMed
    Score: 0.009
  114. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int. 2010 Mar; 30(5):591-8.
    View in: PubMed
    Score: 0.009
  115. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010 Mar; 69(3):529-35.
    View in: PubMed
    Score: 0.009
  116. Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford). 2009 May; 48(5):513-9.
    View in: PubMed
    Score: 0.009
  117. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood). 2009 Mar; 234(3):354-60.
    View in: PubMed
    Score: 0.009
  118. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
    View in: PubMed
    Score: 0.008
  119. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008 May 15; 59(5):721-9.
    View in: PubMed
    Score: 0.008
  120. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008 Mar; 58(3):843-53.
    View in: PubMed
    Score: 0.008
  121. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007 Jan; 56(1):265-73.
    View in: PubMed
    Score: 0.007
  122. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007; 16(6):401-9.
    View in: PubMed
    Score: 0.007
  123. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15; 353(24):2550-8.
    View in: PubMed
    Score: 0.007
  124. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.
    View in: PubMed
    Score: 0.007
  125. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol. 2004 Dec; 31(12):2390-4.
    View in: PubMed
    Score: 0.006
  126. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep; 50(9):2858-68.
    View in: PubMed
    Score: 0.006
  127. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004 Jan; 121(1):142-9.
    View in: PubMed
    Score: 0.006
  128. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol. 2003 Jun-Dec; 10(2-4):203-11.
    View in: PubMed
    Score: 0.006
  129. Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum. 2003 Mar; 48(3):737-45.
    View in: PubMed
    Score: 0.006
  130. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
    View in: PubMed
    Score: 0.006
  131. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul; 46(7):1820-9.
    View in: PubMed
    Score: 0.005
  132. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001 Jun; 44(6):1466-7.
    View in: PubMed
    Score: 0.005
  133. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 1998; 7(5):355-60.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES